Safety of chemotherapy of MDR/XDR-TB patients in high HIV prevalence settings
The review used 61 literature sources to discuss 13 publications devoted to safety of treatment of HIV-associated drug-resistant tuberculosis using basic and new regimens of chemotherapy. According to the literature, no additive toxic effects were detected during treatment with anti-tuberculosis and...
Saved in:
| Main Authors: | A. V. Kukurika, E. I. Veselova, L. E. Parolina, O. V. Lovacheva |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2022-12-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1693 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021
by: E. S. Khimova, et al.
Published: (2023-07-01) -
Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities
by: Kai Ling Chin, et al.
Published: (2024-01-01) -
Genotypic and Phenotypic Methods in the Detection of MDR-TB and Evolution to XDR-TB
by: Natalia Zaporojan, et al.
Published: (2025-07-01) -
TB financing in East Europe promotes unnecessary hospital admissions: the case of Armenia
by: Laura Gillini, et al.
Published: (2013-03-01) -
Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort studyResearch in context
by: Yousra Kherabi, et al.
Published: (2025-09-01)